2031, Oral Spray Market Research Report Booming Worldwide - Benzinga

NPHC Stock  USD 0.0001  0.00  0.00%   
About 55% of Nutra Pharma's shareholders are presently thinking to get in. The analysis of overall sentiment of trading Nutra Pharma Corp pink sheet suggests that some investors are interested at this time. The current market sentiment, together with Nutra Pharma's historical and current headlines, can help investors time the market. In addition, many technical investors use Nutra Pharma Corp stock news signals to limit their universe of possible portfolio assets.
  
2031, Oral Spray Market Research Report Booming Worldwide Benzinga

Read at news.google.com
Google News at Macroaxis
  

Nutra Pharma Fundamental Analysis

We analyze Nutra Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Nutra Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Nutra Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Z Score

Z Score Comparative Analysis

Nutra Pharma is currently under evaluation in z score category among its peers. Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..

Peers

Trending Equities

AAL  1.92   
0%
44.0%
BBY  1.26   
0%
29.0%
TGT  1.04   
0%
24.0%
IBM  0.75   
0%
17.0%
AAPL  0.60   
0%
13.0%
HD  0.31   
0%
7.0%
INTC  0.20   
0%
4.0%
WFC  0.17   
3.0%
0%
CVX  0.24   
5.0%
0%
UPS  0.38   
8.0%
0%
T  0.55   
12.0%
0%
C  0.63   
14.0%
0%
MET  1.52   
35.0%
0%
CVS  1.64   
38.0%
0%
AA  2.14   
49.0%
0%
S  4.30   
100.0%
0%

Complementary Tools for Nutra Pink Sheet analysis

When running Nutra Pharma's price analysis, check to measure Nutra Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nutra Pharma is operating at the current time. Most of Nutra Pharma's value examination focuses on studying past and present price action to predict the probability of Nutra Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nutra Pharma's price. Additionally, you may evaluate how the addition of Nutra Pharma to your portfolios can decrease your overall portfolio volatility.
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk